Ask AI
KRAS Mut LGSOC

CE / CME

Clinical Focus in KRAS-Mutated Low-Grade Serous Ovarian Cancer: Integrating a Novel Dual MEK/FAK Inhibitor Into Practice

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Pharmacists: 0.75 contact hour (0.075 CEUs)

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: February 17, 2026

Expiration: August 16, 2026

Activity

Progress
1 2
Course Completed

References

1. Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma. Adv Anat Path. 2009;16:267-282.

‌2. Bookman MA. Molecular wanderings through the DNA damage response and risk for ovarian cancer. J Natl Cancer Inst. 2014;106;djt350.

3. du Bois A, Baert T, Vergote I. Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Clin Oncol. 2019;37:2398-2405.

4. Poveda AM, Selle F, Hilpert F, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol. 2015;33:3836-3838.

‌5. Monk BJ, Grisham RN, Banerjee S, et al. MILO/ENGOT-ov11: Binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol. 2020;38:3753-3762.

‌6. Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;14:48-52.

7. Manning‐Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin Cancer Res. 2022;28:4456-4465.

8. Dabrafenib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2025.

9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: ovarian cancer. v.3.2025. nccn.org. Accessed February 12, 2026.

10. Van Nieuwenhuysen E, Grisham R, Ray-Coquard IL, et al. Blood ctDNA vs tumor tissue screening for the detection of KRAS mutations in low-grade serous ovarian cancer. ESMO Open. 2025;10:105198

11. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.

12. Gershenson DM, Miller A, Brady WE, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399:541-553.

13. Grisham RN, Vergote I, Banerjee S, et al. Molecular results and potential biomarkers identified from the phase 3 MILO/ENGOT-ov11 study of binimetinib versus physician choice of chemotherapy in recurrent low-grade serous ovarian cancer. Clin Cancer Res. 2023;29:4068-4075.

14. Manning-Geist BL, Sullivan MW, Zhou Q, et al. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities. Gynecol Oncol. 2024;188:52-57.

15. Slomovitz BM, Cibula D, Weiguo Lv, et al. Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: results in mismatch repair-deficient tumors. J Clin Oncol. 2025;43:251-259.

‌16. Ray-Coquard I, Pignata S, Lee JY, et al. First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib or atezolizumab + bevacizumab for persistent/recurrent rare epithelial ovarian cancer. Presented at: 2023 European Society for Medical Oncology Annual Conference. October 20-24, 2023. Abstract 747MO.

17. Banerjee S, Krebs MG, Greystoke A, et al. Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial. Nat Med. 2025;31:3074-3080.

‌18. Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025;43:2782-2792.

‌19. Avutometinib and defactinib [prescribing information]. Needham, Massachusetts: Verastem Oncology; 2025.

20.Grisham R, Monk BJ, Van Nieuwenhuysen E, et al. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer. Int J Gynecol Cancer. 2025;35:101832.